Skip to main content
EJNMMI Research

Table 3 Biphasic analysis of blood pharmacokinetics of 111In- CHX-A"-panitumumab following i

From: In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

Tumor site

Injection route

Blood clearance

  

α a (h)

β (h)

r 2

None

i.v.

1.2

18.6

0.996

s.c.

i.v.

0.6

10.4

0.998

None

i.p.

-

19.3

0.98

i.p.

i.p.

-

24.9

0.917

  1. aNon-tumor bearing mice or mice bearing s.c. or i.p. LS-174T xenografts were injected by intravenous or intraperitoneal injection with approximately 7.5 μCi of 111In- CHX-A"-panitumumab F(ab')2. Blood samples (10 μL) were drawn over a 1-week period and measured in a γ-counter. The percentage of injected dose per milliliter plotted and the T1/2α- and T1/2β-phase values calculated using SigmaPlot 9.
Back to article page